BSE · 531752
Biogen Pharmachem Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹-0 Cr — a -24.44% net margin, versus 81.07% the period before.
Shareholding
As of 2026-06-30
- Public100%
- DII0%
2,93,626 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 3× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Finance & Investments · ranked #324 of 600 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Bajaj Finance Limited | ₹6,55,904 Cr | 119.85 | 5.75 | 16.68% | 23.34% |
| Life Insurance Corporation of India | ₹5,34,905 Cr | 9.31 | 3.01 | 32.53% | 10.69% |
| Bajaj Finserv Ltd. | ₹3,05,609 Cr | 120.09 | 3.92 | 12.58% | 6.58% |
| Shriram Finance Limited | ₹2,41,695 Cr | 21.36 | 2.29 | 15.21% | 22.94% |
| Jio Financial Services Ltd. | ₹1,63,065 Cr | 574.3 | 1.17 | 1.17% | 0.44% |
| Tata Capital Limited | ₹1,53,197 Cr | 28.17 | 3.43 | 10.57% | 16.53% |
| Cholamandalam Investment & Finance Company Ltd. | ₹1,51,402 Cr | 91.88 | 4.97 | 17.18% | 16.84% |
| Bajaj Holdings & Investment Ltd. | ₹1,22,089 Cr | 47.41 | 1.67 | 11.33% | 0.95% |
| Muthoot Finance Limited | ₹1,20,790 Cr | 11.41 | 3.09 | 27.06% | 33.93% |
| Billionbrains Garage Ventures Ltd. | ₹1,20,660 Cr | 173.27 | 12.43 | 21.58% | 44.85% |
| Biogen Pharmachem Industries Ltd.(this company) | ₹32 Cr | 30 | 0.32 | 0.87% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashBiogen Pharmachem Industries Ltd. (symbol: 531752) has a market capitalization of Rs 34 Cr. The company reported an EPS of 0.01 and a ROE of 86.74%. Its debt-to-equity ratio is 0. Book value per share stands at 0.94. The 52-week high for the share price was 0.93 and the 52-week low was 0.27.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Return on equity (ROE) is high at 86.74%.
Negatives
- −Promoter shareholding is 0% as of June 30, 2026.
- −The company reported a negative profit margin of 0% and a net loss of Rs -0.29 Cr in March 2025.
- −Revenue declined from Rs 2.38 Cr in March 2024 to Rs 1.20 Cr in March 2025.
- −Earnings per share (EPS) was negative at -0.004 in March 2025.
Financial Performance
In the fiscal year ending March 2024, Biogen Pharmachem Industries Ltd. reported revenue of Rs 2.38 Cr and a net profit of Rs 1.93 Cr. However, for the fiscal year ending March 2025, revenue decreased to Rs 1.20 Cr and the company reported a net loss of Rs -0.29 Cr. Over the past five years, annual revenue has fluctuated, from Rs 1.62 Cr in March 2021 to Rs 1.20 Cr in March 2025.
Profitability & Returns
The company reported a return on equity (ROE) of 86.74% and a return on capital employed (ROCE) of 0.97%. The profit margin for the latest available annual period is 0%. The earnings per share (EPS) for the fiscal year ending March 2023 was 0.01, increasing to 0.03 in March 2024, before decreasing to -0.004 in March 2025.
Balance Sheet
Biogen Pharmachem Industries Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is reported as 0.94. There are no reported pledged shares by promoters.
Ownership & Pledges
As of June 30, 2026, public shareholding in Biogen Pharmachem Industries Ltd. stood at 99.9989%. Promoter shareholding was 0%. Institutional holding, comprising DII and FII, was 0.0011%. The total number of shareholders was 293,626 as of the same period. There is no information regarding promoter share pledges.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Biogen Pharmachem Industries Ltd.share price & fundamentals